AIM: To compare two different anti-vascular endothelial growth factor(anti-VEGF) treatment regimens'-a priori pro re nata(PrN) and PrN regimen following^(th)e loading phaseanatomical and functional results in neovascu...
详细信息
AIM: To compare two different anti-vascular endothelial growth factor(anti-VEGF) treatment regimens'-a priori pro re nata(PrN) and PrN regimen following^(th)e loading phaseanatomical and functional results in neovascular agerelated macular degeneration(n AMD) patients. METHODs: Totally 544 n AMD patients followed and treated with aflibercept(n=135) and ranibizumab(n=409)at 9 different centers between 2013 and 2015 were enrolled into^(th)is retrospective multicenter study. Patients with initial best corrected visual acuity(BCVA) interval of 1.3-0.3(log mar) and a minimum follow-up of 12 mo were included. Patients under two different regimens-a priori pro re nata(1+PrN) or 3 consecutive intravitreal injections followed by a PrN regimen(3+PrN)-were compared in BCVA at 3^(th), 6^(th) and 12^(th) months, and in central macular^(th)ickness(CMT) at 6^(th) and 12^(th) months. The total study group, intravitreal ranibizumab(IVr) and intravitreal aflibercept(IVA) groups were evaluated separately. rEsULTs: The mean CMT decreased in^(th)e 1+PrN(n=101) regimen from 407 to 358 and 340 μm and in^(th)e 3+PrN(n=443) group from 398 to 318 and finally to 310 μm at months 6 and 12, respectively. Anatomically,^(th)e CMT reduction at 6^(th) month(48.5 vs 76.4;Ps statistically significant in favor of 3+PrN group. BCVA changed in 1+PrN group from 0.77 to 0.78, 0.75 and 0.75;in 3+PrN group from 0.81 to 0.69, 0.72, and 0.76 at months 3, 6, and 12, respectively. Visual gain was statistically better in 3+PrN group at 3^(th) month(-0.01 vs 0.12;Pr group, CMT reduction was in greater in 3+PrN at 6^(th)(44 vs 72) and 12^(th) month(61 vs 84), but statistically insignificant. The 3+PrN group revealed statistically better visual results at 3^(th) month(-0.02 vs 0.11, Proup, although statistically insignificant, CMT reduction(61 vs 89, 6^(th) month;85 vs 97, 12^(th) month) and visual gain(0.02 vs 0.16;0.02 vs 0.14;0.05 vs 0.11) was found in favor of 3+PrN group
暂无评论